AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: IOVA
Report Date: 2026-04-09
Full Report: https://amaly.io/stock/IOVA

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: This report evaluates Iovance Biotherapeutics (IOVA), a biotechnology company focused on cancer immunotherapies, for Shariah compliance. The analysis reveals non-compliance primarily due to elevated liquidity ratios exceeding key thresholds across major standards, despite permissible business activities in ethical healthcare. Financial screening shows low debt and minimal non-permissible income, but cash holdings raise concerns over potential riba exposure. Index exclusion reinforces the non-compliant status, with a quality rating of B indicating moderate concerns. Investors may consider purification for incidental interest income while monitoring financial improvements.

Primary Compliance Concerns:
- Liquidity ratio exceeds 30-33% thresholds across AAOIFI, MSCI, and S&P standards
- Historical interest income volatility, though current at 3.91% below 5% threshold

Purification Requirement: 3.91%
Index Inclusion: Excluded from all major Shariah indices

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 5.7%
Liquidity Ratio: 38.0%
Interest Income Ratio: 0.0%
Purification Required: 3.91%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2026-01-31

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-24T12:00:00Z

---
Full interactive report: https://amaly.io/stock/IOVA
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.